A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (NCT06897930)
A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Who can join: Review the eligibility criteria below.
Location: Research Site — San Francisco, California
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Research Site — San Francisco, California
- Research Site — Stanford, California
- Research Site — Tampa, Florida
- Research Site — Atlanta, Georgia
- Research Site — Chicago, Illinois
- Research Site — Baltimore, Maryland
- Research Site — Bethesda, Maryland
- Research Site — Boston, Massachusetts
- Research Site — St Louis, Missouri
- Research Site — New York, New York
- Research Site — Syracuse, New York
- Research Site — Chapel Hill, North Carolina
- Research Site — Charlotte, North Carolina
- Research Site — Richmond, Virginia
- Research Site — Seattle, Washington
- Research Site — Seattle, Washington
- Research Site — Darlinghurst,
- Research Site — Melbourne,
- Research Site — Toronto,
- Research Site — Bristol,
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lupus Erythematosus, Systemic
- A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) — Phoenix, Arizona
- Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus — Denver, Colorado
- A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Homewood, Alabama
- Engagement in CHildhood-Onset Systemic Lupus — The Bronx, New York
- A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus — Huntington Park, California
- A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus — Tucson, Arizona
Explore by condition: All Lupus Erythematosus, Systemic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.